Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.
AbuAlrob. Majd A MA; Hussein. Abdullah A; Abdellatif. Rand R; Itbaisha. Adham A; Zammar. Khaled K; Mesraoua. Boulenouar B
Key Findings
- Starting a GLP‑1 receptor agonist cut the risk of seizure recurrence by about 18% (HR 0.82).
- Hospitalization risk dropped dramatically (HR 0.35) and all‑cause mortality fell by 60% (HR 0.40).
- The benefit was seen across several outcomes, though the effect on ICU admission was modest and not statistically significant.
Practical Outcomes
- For biohackers focused on metabolic health and brain function, GLP‑1 drugs like tirzepatide may offer added neuroprotective benefits beyond glucose control. While the data are encouraging, they come from a retrospective analysis, so you should wait for prospective trials before making it a core part of a seizure‑prevention protocol. In the meantime, consider GLP‑1 agonists as a potential dual‑action therapy if you already need diabetes management, but discuss risks and benefits with a clinician.
Summary
A big study looked at adults who have both epilepsy and type 2 diabetes and started them on GLP‑1 drugs like tirzepatide. Compared to other diabetes meds, those on GLP‑1 drugs had fewer seizure relapses, fewer hospital stays, and lower death rates. The results are promising but still need confirmation in future trials.
Abstract
To examine whether initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes. We conducted a retrospective cohort study using de-identified electronic health records from the TriNetX Research Network (January 2003-August 2025), including adults ≥18 years with ≥3 epilepsy or recurrent seizure diagnoses. Patients initiating a GLP-1 RA (exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, or tirzepatide) without prior comparator therapy were compared with those initiating other glucose-lowering agents (sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase 4 inhibitors, sulfonylureas, or insulin) without GLP-1 RA exposure. Propensity score matching (1:1) was performed on 82 covariates, yielding 8688 matched pairs. Outcomes were assessed using Cox proportional hazards models. After matching, the mean age was 52.6 years, and 67.6% were female. Median follow-up was 514 days (interquartile range [IQR] 671) for GLP-1 RA initiators and 415 days (IQR 769) for comparators. GLP-1 RA initiation was associated with lower risk of seizure recurrence (HR .82, 95% confidence interval [CI] .78-.86; RD -2.1%), hospitalization (HR .35, 95% CI .29-.43; RD -2.6%), and all-cause mortality (HR .40, 95% CI .34-.47; RD -4.8%). Associations with status epilepticus (HR .75, 95% CI .66-.85; RD -.7%) and ICU admission (HR .82, 95% CI .69-.96; RD -.3%) were smaller; the latter was not statistically significant. In this large multinational cohort, GLP-1 RA initiation was associated with reduced risks of seizure recurrence, hospitalization, and mortality compared with other glucose-lowering therapies. These hypothesis-generating findings warrant confirmation in prospective studies before translation into clinical practice.
Study Information
pubmed
2025
2025-11-18T00:00:00.000Z
10.1111/epi.70022
15